





Factory : Plot No. 801/P, GIDC Estate, ANKLESHWAR 393 002. (Gujan Regd. Office : Plot No. 801/P, GIDC Estate, ANKLESHWAR 393 002. (Gujan : [02646] 223462, 227530 Fax : (02646) 250126 E-mail : contact@norrispharma.com

May 21 2024

To,

Department of Corporate Service BSE Limited,

Registered Office: Floor 25, P. J. Towers, Dalal Street, Fort, Mumbai 400001.

Subject: Intimation of Board Meeting as per Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements [LODR]) Regulations, 2015 for approval of Standalone Audited Financial Results for the quarter & year ended March 31 2024 as per Regulation 33 of the SEBI (LODR) Regulations, 2015.

Reference: NORRIS MEDICINES LIMITED Script Code: 524414.

Dear Sir / Madam,

We hereby inform you that pursuant to Regulation 29 read with Regulation 33 of SEBI (LODR) Regulation, 2015, the meeting of Board of Directors of the Company NORRIS MEDICINES LIMITED will be held on Wednesday the May 29 2024 at the registered office of the Company to transact the following business:

- 1. To consider and approve IND-AS compliant Standalone Audited Financial Results along with Audit Report for the quarter and year ended on 31st March, 2024 pursuant to regulation 33 of Listing Obligation and Disclosure Requirement, 2015;
- 2. To approve IND-AS compliant Standalone Statement of Assets and Liabilities for the year ended 31st March, 2023;
- 3. Any other business with permission of Chair.

The approved results will be uploaded on BSE Limited website after conclusion of the said meeting.

Thanking you, Yours faithfully, For NORRIS MEDICINES LIMITED

Name: VIMAL DHIRENDRA SHAH

DIN: 01506655 Designation: Director